Temperature-controlled supply chain solutions firm Cryoport has announced the opening ... and distribution solution for the ...

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its novel Nectin-4 targeting ADC (R&D code: 9MW2821) has received IND approval for two clinical ...

Q3 2024 Earnings Call Transcript November 6, 2024 Coherus BioSciences, Inc. beats earnings expectations. Reported EPS is $-0.01, expectations were $-0.1. Operator: Good day, and thank you for standing ...

Learn about the usage of process raman spectroscopy in the optimization of bioreactor monitoring and then improvement of ...

So, we have been diversifying our supply chain to ensure proximity to ... that target cancerous cells without affecting healthy ones. This innovation could revolutionise cancer treatment, making it ...

Telangana attracts ₹36,000 crore investments in life sciences, becoming a global leader in pharmaceutical manufacturing and R ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 14, 2024 /PRNewswire/ -- Harbour BioMed (the Company; HK ...

FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025 Company makes significant progress toward potential commerciali ...

Presented preclinical and interim clinical data for PBFT02 in FTD- GRN at the ESGCT conference: In October, the company delivered an oral presentation highlighting preclinical data for PBFT02 at the ...

Donald Trump returning to the White House triggered new index records in the US, and major UK companies are likely to feel ...

Global Ophthalmological Devices Market Size Expanding to Reach Value of USD ... partnerships, and cell-based treatments. Advancements in eye surgery, such as phacoemulsification and laser-assisted ...

Treatment with CNTY-101 continued to be safe and generally well tolerated with no dose-limiting toxicities reported, no additional cases of immune effector cell-associated neurotoxicity ... at Century ...